Delivery Order SPE2DB22D3016-SPE2DB25FBGU7
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units. This competitive award, valued at approximately $45K, represents a firm fixed-price delivery order with an ultimate completion date of August 21, 2025. The contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 10, 2025, for the supply of Dapagliflozin 5 mg tablets (30-count units) valued at $10,269.40 under a firm fixed price contract. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical product will be delivered...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,376.58 to AmerisourceBergen Drug Corp for the supply of Dapagliflozin 10 mg tablets (30-count packaging) on August 4, 2025, with completion targeted for August 5, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a contract ceiling value of $10,763.89. This firm fixed-price delivery order, which reaches ultimate completion on August 14, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $11,089.97. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for ultimate completion on September 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 with a ceiling value of $10,996.65. This is a firm fixed price delivery order with no set-aside designation, completed competitively through open procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 28, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package, valued at $4,022.60. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is expected to reach completion by September 9, 2025. The delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion prime vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30, valued at $29,475.49 under a firm fixed-price contract. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), which carries a ceiling value of $999,999,999.00 through December 2026. The award carries no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30, with a contract value of $4,353.54 and completion deadline of September 10, 2025. This non-set-aside, firm fixed-price delivery order represents a continuation of AmerisourceBergen's substantial role as a pharmaceutical supplier to the federal government. The award is executed under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a ceiling value of $5,358.11 and a firm fixed price structure. The contract represents a non-set-aside, competitively awarded delivery order with an ultimate completion date of July 25, 2025. This award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBGU7Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count packages) valued at $2,663.10 with a firm fixed price structure. This contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle running through December 2026. The delivery order carries no set-aside designation and was competitively awarded, with performance scheduled for completion by September 2, 2025, at AmerisourceBergen's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal military and veteran healthcare systems through its comprehensive portfolio of medications and medical supplies. The company's extensive experience fulfilling federal procurement requirements across multiple therapeutic domains—including diabetes medications, neurological treatments, antibiotics, and specialty pharmaceuticals—demonstrates its capability to meet DLA medical supply chain needs. This delivery order for Dapagliflozin, a diabetes treatment medication, is consistent with the company's established role supplying pharmaceutical products to support military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 8/29/25 |